Prognostic value of peripheral blood neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, pan-immune-inflammation value and systemic immune-inflammation index for the efficacy of immunotherapy in patients with advanced gastric cancer

References

• Sung H, Ferlay J, Siegel RL et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021;71:209–249. doi: 10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Arnold M, Abnet CC, Neale RE et al. Global burden of 5 major types of gastrointestinal cancer. Gastroenterology 2020;159:335–349.e15. doi: 10.1053/j.gastro.2020.02.068
   PubMed Web of Science ®Google Scholar
• Wang FH, Zhang XT, Li YF et al. The Chinese Society of Clinical Oncology (CSCO), Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. Cancer Commun. (Lond). 2021;41:747–795. doi: 10.1002/cac2.12193
   PubMed Web of Science ®Google Scholar
• Allemani C, Matsuda T, Di Carlo V et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 2018;391:1023–1075. doi: 10.1016/S0140-6736(17)33326-3
   PubMed Web of Science ®Google Scholar
• Jim MA, Pinheiro PS, Carreira H et al. Stomach cancer survival in the United States by race and stage (2001–2009): findings from the CONCORD-2 study. Cancer 2017;123(Suppl. 24):4994–5013. doi: 10.1002/cncr.30881
   PubMedGoogle Scholar
• Li Y, Feng A, Zheng S et al. Recent estimates and predictions of 5-year survival in patients with gastric cancer: a model-based period analysis. Cancer Control. 2022;29:10732748221099227. doi: 10.1177/10732748221099227
   Web of Science ®Google Scholar
• Li J, Cui T, Huang Z et al. Analysis of risk factors for lymph node metastasis and prognosis study in patients with early gastric cancer: a SEER data-based study. Front. Oncol. 2023;13:1062142. doi: 10.3389/fonc.2023.1062142
   PubMedGoogle Scholar
• Smyth EC, Nilsson M, Grabsch HI et al. Gastric cancer. Lancet 2020;396:635–648. doi: 10.1016/S0140-6736(20)31288-5
   PubMed Web of Science ®Google Scholar
• Shitara K, Van Cutsem E, Bang YJ et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 Phase III randomized clinical trial. JAMA Oncol. 2020;6:1571–1580. doi: 10.1001/jamaoncol.2020.3370
   PubMed Web of Science ®Google Scholar
• Ajani JA, D'Amico TA, Bentrem DJ et al. Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Canc. Netw. 2022;20:167–192. doi: 10.6004/jnccn.2022.0008
   PubMed Web of Science ®Google Scholar
• Lordick F, Carneiro F, Cascinu S et al. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 2022;33:1005–1020. doi: 10.1016/j.annonc.2022.07.004
   PubMed Web of Science ®Google Scholar
• Kim TH, Kim IH, Kang SJ et al. Korean Practice Guidelines for Gastric Cancer 2022: an evidence-based, multidisciplinary approach. J. Gastric Cancer 2023;23:3–106. doi: 10.5230/jgc.2023.23.e11
   PubMed Web of Science ®Google Scholar
• Fuchs CS, Doi T, Jang RW et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: Phase II Clinical KEYNOTE-059 Trial. JAMA Oncol. 2018;4:e180013. doi: 10.1001/jamaoncol.2018.0013
   PubMed Web of Science ®Google Scholar
• Bang YJ, Kang YK, Catenacci DV et al. Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study. Gastric Cancer 2019;22:828–837. doi: 10.1007/s10120-018-00909-5
   PubMed Web of Science ®Google Scholar
• Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature 2017;541:321–330. doi: 10.1038/nature21349
   PubMed Web of Science ®Google Scholar
• Janjigian YY, Shitara K, Moehler M et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, Phase III trial. Lancet 2021;398:27–40. doi: 10.1016/S0140-6736(21)00797-2
   PubMed Web of Science ®Google Scholar
• Chao J, Fuchs CS, Shitara K et al. Assessment of pembrolizumab therapy for the treatment of microsatellite instability-high gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 clinical trials. JAMA Oncol. 2021;7:895–902. doi: 10.1001/jamaoncol.2021.0275
   PubMed Web of Science ®Google Scholar
• Zhang Y, Yang Y, Chen Y et al. PD-L1: biological mechanism, function, and immunotherapy in gastric cancer. Front. Immunol. 2022;13:1060497. doi: 10.3389/fimmu.2022.1060497
   PubMed Web of Science ®Google Scholar
• Cheng Y, Bu D, Zhang Q et al. Genomic and transcriptomic profiling indicates the prognosis significance of mutational signature for TMB-high subtype in Chinese patients with gastric cancer. J. Adv. Res. 2023;51:121–134. doi: 10.1016/j.jare.2022.10.019
   PubMed Web of Science ®Google Scholar
• Yang Y, Shi Z, Bai R et al. Heterogeneity of MSI-H gastric cancer identifies a subtype with worse survival. J. Med. Genet. 2021;58:12–19. doi: 10.1136/jmedgenet-2019-106609
   PubMed Web of Science ®Google Scholar
• Wang M, Ran X, Leung W et al. ATR inhibition induces synthetic lethality in mismatch repair-deficient cells and augments immunotherapy. Genes Dev. 2023;37:929–943. doi: 10.1101/gad.351084.123
   PubMed Web of Science ®Google Scholar
• Yeong J, Lum H, Teo CB et al. Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy. Gastric Cancer. 2022;25:741–750. doi: 10.1007/s10120-022-01301-0
   PubMed Web of Science ®Google Scholar
• Tsao MS, Kerr KM, Kockx M et al. PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of blueprint Phase II Project. J. Thorac. Oncol. 2018;13:1302–1311. doi: 10.1016/j.jtho.2018.05.013
   PubMed Web of Science ®Google Scholar
• Paver EC, Cooper WA, Colebatch AJ et al. Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumors: a guide to immunohistochemistry implementation and interpretation. Pathology 2021;53:141–156. doi: 10.1016/j.pathol.2020.10.007
   PubMed Web of Science ®Google Scholar
• Xu X, Chen J, Li W et al. Immunology and immunotherapy in gastric cancer. Clin. Exp. Med. 2023;23:3189–3204. doi: 10.1007/s10238-023-01104-2
   PubMed Web of Science ®Google Scholar
• Hara K, Aoyama T, Yamada T et al. The prognostic value of the perioperative systemic inflammation score for patients with advanced gastric cancer. Anticancer Res. 2020;40:1503–1512. doi: 10.21873/anticanres.14095
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhang L, Duan S et al. Single and combined use of the platelet-lymphocyte ratio, neutrophil-lymphocyte ratio, and systemic immune-inflammation index in gastric cancer diagnosis. Front. Oncol. 2023;13:1143154. doi: 10.3389/fonc.2023.1143154
   PubMed Web of Science ®Google Scholar
• Ock CY, Nam AR, Lee J et al. Prognostic implication of antitumor immunity measured by the neutrophil-lymphocyte ratio and serum cytokines and angiogenic factors in gastric cancer. Gastric Cancer 2017;20:254–262. doi: 10.1007/s10120-016-0613-5
   PubMed Web of Science ®Google Scholar
• Mosca M, Nigro MC, Pagani R et al. Neutrophil-to-lymphocyte ratio (NLR) in NSCLC, gastrointestinal, and other solid tumors: immunotherapy and beyond. Biomolecules 2023;13:1803. doi: 10.3390/biom13121803
   PubMed Web of Science ®Google Scholar
• Qiu Y, Zhang Z, Chen Y. Prognostic value of pretreatment systemic immune-inflammation index in gastric cancer: a meta-analysis. Front. Oncol. 2021;11:537140. doi: 10.3389/fonc.2021.537140
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur. J. Cancer 2009;45:228–247. doi: 10.1016/j.ejca.2008.10.026
   PubMed Web of Science ®Google Scholar
• Montagne JM, Jaffee EM, Fertig EJ. Multiomics empowers predictive pancreatic cancer immunotherapy. J. Immunol. 2023;210:859–868. doi: 10.4049/jimmunol.2200660
   PubMed Web of Science ®Google Scholar
• Nie Y, Zhao W, Lu L et al. Predictive biomarkers and new developments of immunotherapy in gastric cancer: a 2023 update. Am. J. Cancer Res. 2023;13:3169–3184
   PubMed Web of Science ®Google Scholar
• Ravindranathan D, Master VA, Bilen MA. Inflammatory markers in cancer immunotherapy. Biology (Basel). 2021;10: 325. doi: 10.3390/biology10040325
   PubMedGoogle Scholar
• Sun D, Liu J, Zhang L. Establishment of tumor immune microenvironment classification model to select patients sensitive to immunotherapy. J. Thorac. Oncol. 2023;18:e111–e112. doi: 10.1016/j.jtho.2023.07.003
   PubMed Web of Science ®Google Scholar
• Adegoke NA, Gide TN, Mao Y et al. Classification of the tumor immune microenvironment and associations with outcomes in patients with metastatic melanoma treated with immunotherapies. J. Immunother. Cancer 2023;11:e007144. doi: 10.1136/jitc-2023-007144
   PubMed Web of Science ®Google Scholar
• Belkouchi Y, Nebot-Bral L, Lawrance L et al. Predicting immunotherapy outcomes in patients with MSI tumors using NLR and CT global tumor volume. Front. Oncol. 2022;12:982790. doi: 10.3389/fonc.2022.982790
   PubMedGoogle Scholar
• Zhou K, Cao J, Lin H et al. Prognostic role of the platelet to lymphocyte ratio (PLR) in the clinical outcomes of patients with advanced lung cancer receiving immunotherapy: a systematic review and meta-analysis. Front. Oncol. 2022;12:962173. doi: 10.3389/fonc.2022.962173
   PubMed Web of Science ®Google Scholar
• Wu Y, Jiang M, Qin Y et al. Single and combined use of neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and carcinoembryonic antigen in diagnosing gastric cancer. Clin. Chim. Acta 2018;481:20–24. doi: 10.1016/j.cca.2018.02.027
   PubMed Web of Science ®Google Scholar
• Zhang LX, Wei ZJ, Xu AM et al. Can the neutrophil-lymphocyte ratio and platelet-lymphocyte ratio be beneficial in predicting lymph node metastasis and promising prognostic markers of gastric cancer patients? Tumor maker retrospective study. Int. J. Surg. 2018;56:320–327. doi: 10.1016/j.ijsu.2018.06.037
   PubMed Web of Science ®Google Scholar
• Shimada H, Takiguchi N, Kainuma O et al. High preoperative neutrophil-lymphocyte ratio predicts poor survival in patients with gastric cancer. Gastric Cancer 2010;13:170–176. doi: 10.1007/s10120-010-0554-3
   PubMed Web of Science ®Google Scholar
• Zhang S, Xia K, Chang Y et al. LRP2 and DOCK8 are potential antigens for mRNA vaccine development in immunologically ‘cold’ KIRC tumors. Vaccines (Basel). 2023;11:396. doi: 10.3390/vaccines11020396
   PubMed Web of Science ®Google Scholar
• Pennel K, Park JH, McMillan DC et al. Signal interaction between the tumor and inflammatory cells in patients with gastrointestinal cancer: implications for treatment. Cell. Signal. 2019;54:81–90. doi: 10.1016/j.cellsig.2018.11.013
   PubMed Web of Science ®Google Scholar
• Liu YT, Sun ZJ. Turning cold tumors into hot tumors by improving T-cell infiltration. Theranostics 2021;11:5365–5386. doi: 10.7150/thno.58390
   PubMed Web of Science ®Google Scholar
• White K, Connor K, Meylan M et al. Identification, validation and biological characterisation of novel glioblastoma tumor microenvironment subtypes: implications for precision immunotherapy. Ann. Oncol. 2023;34:300–314. doi: 10.1016/j.annonc.2022.11.008
   PubMed Web of Science ®Google Scholar
• Duan Q, Zhang H, Zheng J et al. Turning cold into hot: firing up the tumor microenvironment. Trends Cancer 2020;6:605–618. doi: 10.1016/j.trecan.2020.02.022
   PubMed Web of Science ®Google Scholar
• Ortiz-Muñoz G, Brown M, Carbone CB et al. In situ tumor arrays reveal early environmental control of cancer immunity. Nature 2023;618:827–833. doi: 10.1038/s41586-023-06132-2
   PubMed Web of Science ®Google Scholar
• Sun R, Limkin EJ, Vakalopoulou M et al. A radiomics approach to assess tumor-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Lancet Oncol. 2018;19:1180–1191. doi: 10.1016/S1470-2045(18)30413-3
   PubMed Web of Science ®Google Scholar
• Guo W, Cai S, Zhang F et al. Systemic immune-inflammation index (SII) is useful to predict survival outcomes in patients with surgically resected non-small cell lung cancer. Thorac. Cancer 2019;10:761–768. doi: 10.1111/1759-7714.12995
   PubMed Web of Science ®Google Scholar
• Huang H, Liu Q, Zhu L et al. Prognostic value of preoperative systemic immune-inflammation index in patients with cervical cancer. Sci. Rep. 2019;9:3284. doi: 10.1038/s41598-019-39150-0
   PubMed Web of Science ®Google Scholar
• Xue R, Zhang Q, Cao Q et al. Liver tumor immune microenvironment subtypes and neutrophil heterogeneity. Nature 2022;612:141–147. doi: 10.1038/s41586-022-05400-x
   PubMed Web of Science ®Google Scholar
• Faria A, Andrade SS, Peppelenbosch MP et al. Platelets in aging and cancer-“double-edged sword”. Cancer Metastas. Rev. 2020;39:1205–1221. doi: 10.1007/s10555-020-09926-2
   PubMed Web of Science ®Google Scholar
• Hirahara N, Matsubara T, Fujii Y et al. Comparison of the prognostic value of immunoinflammation-based biomarkers in patients with gastric cancer. Oncotarget 2020;11:2625–2635. doi: 10.18632/oncotarget.27653
   PubMedGoogle Scholar
• Yang L, Zhang Y. Tumor-associated macrophages: from basic research to clinical application. J. Hematol. Oncol. 2017;10:58. doi: 10.1186/s13045-017-0430-2
   PubMed Web of Science ®Google Scholar